Today, TheraPanacea and Indivi are proud to announce a groundbreaking partnership to advance precision drug development in Alzheimer’s disease. This strategic alliance will leverage a bimodal approach, utilizing brain imaging and deep motor and cognitive phenotyping. Together, we aim to develop differentiated biomarker and diagnostic signatures while fostering the use of AI-driven precision medicine techniques to train bespoke algorithms as predictive enrichment tools and companion diagnostics.
Read the full article here: https://lnkd.in/e5ARP2bF
Why the Time is Now
The population-level effect size of amyloid-depleting treatments in early Alzheimer’s disease remains modest due to its heterogeneous nature. Precision drug development offers a critical opportunity to enhance the benefit-to-risk ratio of these interventions in early Alzheimer’s disease. Advancing AI-based companion diagnostics will be pivotal in unlocking the true responder value of amyloid-depleting therapies.
The clock is ticking on personalizing drug development in Alzheimer’s disease. Join us next week at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid to learn more!
About TheraPanacea
TheraPanacea is a TechBio company at the forefront of leveraging state-of-the-art research in computer science, applied mathematics, artificial intelligence, and multiomics approaches. Our mission is to enhance treatment implementation and biomarker discovery through cutting-edge software solutions certified as medium- to high-risk medical devices.
About Indivi
Indivi is a TechBio company focused on developing functional biomarkers as drug development tools for neurological diseases. These biomarkers are sensor-derived measurements generated from smartphone-based assessments of cognition, motion, vision, and voice.
Acknowledgments
We extend our gratitude to Nikos Paragios, Catherine Martineau-Huynh, Alexandre Favre, Gizem Temiz, Olivier Colliot, Neil Oxtoby, Quentin Spinat, Audrey Duran, Carlos Santos García, Marius Schmidt-Mengin, Olivier Teboul, and Claire Lamotte for their contributions to this effort.